600594 益佰制药
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-3.741-14.091--3.599-14.140
总资产报酬率 ROA (%)-2.395-8.740--2.227-9.137
投入资产回报率 ROIC (%)-2.745-10.031--2.563-10.474

边际利润分析
销售毛利率 (%)57.66559.66261.84869.47170.963
营业利润率 (%)-10.761-16.318-14.3634.870-13.745
息税前利润/营业总收入 (%)-9.046-15.622-14.3865.245-13.116
净利润/营业总收入 (%)-11.381-18.001-15.3943.239-16.442

收益指标分析
经营活动净收益/利润总额(%)72.66144.41078.423150.494-53.505
价值变动净收益/利润总额(%)0.1100.069-0.1020.0220.042
营业外收支净额/利润总额(%)-1.5242.4916.095-3.8074.107

偿债能力分析
流动比率 (X)1.6991.593--2.2261.740
速动比率 (X)1.0340.991--1.5951.207
资产负债率 (%)32.89934.029--34.34735.839
带息债务/全部投入资本 (%)21.81321.361--21.84125.137
股东权益/带息债务 (%)337.095342.726--328.028281.679
股东权益/负债合计 (%)196.077186.794--182.676170.342
利息保障倍数 (X)-5.824-14.049-15.8319.479-10.769

营运能力分析
应收账款周转天数 (天)38.70134.6580.00033.28641.814
存货周转天数 (天)330.963276.5840.000253.296267.364